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Abstract
The human immunodeficiency virus type 1 (HIV-1) accessory protein viral protein R (Vpr) is a major determinant for virus-
induced G2/M cell cycle arrest and cytopathicity. Vpr is thought to perform these functions through the interaction with
partner proteins. The NMR structure of Vpr revealed solvent exposed hydrophobic amino acids along helices 1 and 3 of Vpr,
which could be putative protein binding domains. We previously showed that the hydrophobic patch along helix-3 was
important for G2/M blockade and cytopathicity. Mutations of the exposed hydrophobic residues along helix-1 were found
to reduce Vpr-induced cell cycle arrest and cell death as well. The levels of toxicity during virion delivery of Vpr correlated
with G2/M arrest. Thus, the exposed hydrophobic amino acids in the amino-terminal helix-1 are important for the cell cycle
arrest and cytopathicity functions of Vpr.
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Introduction
The HIV-1 accessory protein Vpr has many well-characterized
functions and properties during HIV-1 infection that appear to
be dependent on binding to partner molecules [1,2]. Vpr is
incorporated into budding HIV-1 virions [3], and within cells, Vpr
mostly localizes to the nucleus [4]. These two properties are
thought to allow Vpr to facilitate infection of non-dividing cells, by
mediating the nuclear translocation of the viral pre-integration
complex [5,6]. This is accomplished through an interaction with a
member of the nuclear transport pathway, importin-a [7].
However, the necessity for Vpr during infection of macrophages
is controversial because a recent study has shown no difference in
the infectivity of viruses lacking Vpr versus wild-type viruses [8]. In
addition, in chemically growth-arrested cells, Vpr was found to be
non-essential for infection [9]. Vpr has been reported to increase
the transcriptional activity from the HIV-1 long terminal repeat
(LTR) promoter, as well as several other promoters, through the
binding of cellular transcription factors, such as Sp1 [10,11,12].
The HIV-1 mutation rate during reverse transcription is reduced
by a binding of Vpr with uracil DNA glycosylase 2 and the
incorporation of the latter into viral particles [13,14]. However,
besides bringing UNG2 into viral particles, Vpr is also able to
reduce cellular levels of the enzyme by directly delivering it to an
E3 ubiquitin ligase containing DCAF-1, DDB1, and Cul4
[15,16,17]. Vpr is a major effector of HIV-1 cytopathicity
[18,19,20,21]. Finally, Vpr is able to halt the proliferation of
infected CD4
+ T cells by causing cell cycle arrest at the G2/M
phase [22,23,24,25].
Vpr is a very small protein of only 14 kD (96 amino acids) and
has no known enzymatic activity, no recognizable domains in the
NCBI database, and no structural homologues in the Protein Data
Bank (PDB), so the molecular basis of its actions is not completely
understood [26]. Vpr functions are thought to depend on binding
with partner proteins [1,2]. The NMR structure of full length Vpr
provides some insights into the possible mechanism of Vpr activity
[27]. Vpr forms a bundle of three a-helices folded around a
hydrophobic core with flexible termini. The structure reveals
solvent exposed hydrophobic amino acids along helices 1 and 3 of
Vpr [27]. In principle, hydrophobic patches seek to be solvent
inaccessible and therefore we conjecture that a hydrophobic
substance, perhaps another protein, likely interacts with these
patches. Therefore, we hypothesized that these hydrophobic
patches serve as protein interaction sites that might be important
for Vpr functions.
Separate regions within Vpr have been shown to be critical to
many Vpr functions [28]. Incorporation into budding virions has
been mapped to the amino (N)-terminal half of Vpr, particularly
the amphipathic helix-1 [29,30,31,32,33]. Vpr helices 1 and 2
have also been shown to be important in the nuclear localization
of Vpr [29,30,33,34,35], which depends on an interaction
between Vpr helix-1 and importin-a, an integral component of
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have highlighted a role for the carboxyl (C)-terminal portion of
Vpr in nuclear localization, as well [4,36,37]. The ability of Vpr
to increase transcription from the viral LTR promoter was
mapped to the C-terminal half [38,39]. Historically, the region
containing helix-3 and the flexible C-terminus of Vpr has been
shown to be necessary for G2/M cell cycle arrest [29,30,40].
Thus these distinct portions of Vpr appear to differentially
regulate Vpr functions, likely through the binding of different
partner molecules.
Recently, we published a structure-function based study
exploring the role of the exposed hydrophobic residues along Vpr
helix-3 in cell cycle arrest, nuclear localization, Vpr dimerization,
and cell death [18]. This first look at the role of this hydrophobic
patch found that these residues are indeed important for G2/M
arrest. However, the role of these amino acids in cytotoxicity is less
clear. The levels of death were proportional to the levels of cell cycle
arrest induced by hydrophobic patch mutants duringvirion delivery
of Vpr. However, when these same mutants were expressed during
HIV-1 infection, the levels of cell death were similar to wild type
Vpr, likely due to a G1 arrest of the infected cells as opposed to G2/
M blockade [18].
Although the N-terminal helix-1 of Vpr has not been previously
associated with cell cycle arrest, we hypothesized that the exposed
hydrophobic patch along this a-helix could serve as a protein
interaction region with a partner protein necessary for this
function. We performed a similar structure-function based
approach to test the involvement of the helix-1 exposed
hydrophobic residues in cell cycle arrest and cytopathicity [18].
Mutation of these amino acids reduced G2/M arrest and
cytopathicity during virion delivery of Vpr. Similar to our previous
study [18], cell cycle arrest and cell death were correlated when
Vpr was delivered by non-replicative virions. These data suggest
that the hydrophobic patch along Vpr helix-1 is important during




HEK293T (293T) cells and Jurkat 1.9 cells [18,41,42] were
maintained in RPMI 1640 (Lonza) that was supplemented with
10% fetal calf serum, 50 mM b-mercaptoethanol, 2.4 mM L-
glutamine, and 100 U of penicillin-streptomycin/ml.
HIV virus stock and virion delivery of Vpr
HIV-1 viral stocks were produced in 293T cells by transfection
using ExGen 500 according to the manufacturer’s instructions
(Fermentas). Virion delivery of Vpr has been previously described
[18,41,43,44]. A plasmid encoding a reverse transcriptase mutant
with the vpr gene deleted (pNL4-3e-n-GFPRT
m, VprD22-86; a gift
from E. Freed, National Cancer Institute, NIH) and a plasmid
encoding the VSV-G envelope protein (pLVSV-G) were trans-
fected into 293T cells to produce VSV-G pseudotyped virions.
Plasmids encoding WT and mutant Vpr were co-transfected in
order to transcomplement the Vpr-deficient virus. Jurkat cells were
infected in 12-well plates in the presence of Polybrene (5 mg/ml;
Sigma-Aldrich). Virus was adsorbed for 30 min at 37uCi n5 %
CO2, and then the plates were centrifuged for 30 min at 8006g at
room temperature.
Transfection
An Electro-Cell manipulator (BTX) apparatus was used to
transiently transfect Jurkat cells by electroporation. A total of
4610
6 cells were resuspended to a concentration of 10610
6
cells/ml with 10 to 15 mg of DNA in a 4-mm gap cuvette (Bio-
Rad Laboratories) and electroporated at 260 V and 1,060 mF.
Transfected cells were transferred to fresh supplemented RPMI
and assayed after 3 days. A plasmid encoding the green fluorescent
protein (GFP) was cotransfected at a 1:5 ratio to the Vpr
expression plasmid to identify transfected cells. The human codon-
optimized Vpr plasmid, hVpr [18,41], was used to express WT
Vpr. Mutations of W18 and L22 were generated using a PfuUltra
II (Stratagene) site-directed mutagenesis protocol.
Assays for cell cycle and cell viability
DNA content analysis was performed by propidium iodide (PI)
staining. Cells were fixed with 1% paraformaldehyde in phos-
phate-buffered saline (PBS) for 10 min at room temperature,
washed in PBS, and incubated in 70% ethanol for at least 30 min.
Cells were washed again in PBS and stained with DNA staining
solution (5 mg of PI/ml, 50 mg of RNase/ml, and 0.45 mg of
sodium citrate/ml in PBS) at room temperature for 30 min.
Stained cells were examined using a FACSCalibur flow cytometer
(Becton Dickinson), and a constant number of cells were
measured. Viability of infected cells was assessed by the exclusion
of the vital dye propidium iodide, measured for a constant period
of time (30 sec) per sample. All flow cytometric data were analyzed
by using FlowJo software (Tree Star, Inc.).
Immunoblotting
Jurkat cells, 293T cells, and concentrated virus stocks were lysed
in a 2% sodium dodecyl sulfate (SDS) buffer (2% SDS and 10%
glycerol in 60 mM Tris-HCl [pH 7.5] with 1 U/ml of DNase
[Benzonase nuclease; Novagen] and Complete protease inhibitor
cocktail [Roche]) for at least 30 min at 4uC. A bicinchoninic acid
assay (Pierce) was used to determine protein concentration of the
lysates. Equal masses of protein were loaded onto a 4 to 20% Bis-
Tris SDS gel (Bio-Rad Laboratories) for SDS-polyacrylamide gel
electrophoresis, and protein was transferred to nitrocellulose using
a semidry transfer apparatus (Bio-Rad Laboratories). Nitrocellu-
lose blots were blocked in 5% nonfat milk in 0.1% PBS-Tween 20
(PBS-T). Blots were probed with primary antibody overnight at
4uC, followed by secondary antibody conjugated to horseradish
peroxidase diluted 1:5,000. All antibodies were diluted in 5%
nonfat milk in PBS-T. After each antibody incubation, blots were
washed three times in PBS-T. The bands were imaged by using
enhanced chemiluminescent or SuperSignal West Dura substrates
(Pierce). Densitometry was performed using ImageJ software
(NIH). The primary antibodies used include Vpr antiserum (a gift
from K. Strebel), p24-capsid (AIDS Research and Reference
Reagent Program; 6457), and b-actin (Sigma-Aldrich; A1978).
Results
The core of the Vpr protein (amino acids [AA] 17–77) is
comprised of three a-helices folded around a hydrophobic core
[27]. Figure 1A shows the boundaries of Vpr helix-1 (AA 17–33),
helix-2 (AA 38–50), and helix-3 (AA 56–77) [27]. The animo
(N)- and carboxyl (C)-termini were found to be flexible and
unstructured (Figure 1). Along helices 1 and 3 of Vpr are several
solvent-exposed hydrophobic amino acids (Figure 1, red for amino
acids of helix-1 and blue for those of helix-3). The rest of the Vpr
surface is hydrophilic, with only a few sporadically spaced
hydrophobic amino acids partially exposed to the solvent
environment (Figure 1C, E, and G). Using a previously successful
strategy [18], we employed a structurally based mutagenesis
approach to disrupt the hydrophobic patch on Vpr helix-1. The
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alanine (A) (small, non-polar), serine (S) (polar), or glutamic acid
(E) (charged, highly hydrophilic) in order to disrupt the chemical
nature of the hydrophobic patch to varying degrees. Although L26
is also exposed to the surface of the protein, the side chain has
lipophilic interactions with the core of the protein as well [27]
(Figure 1C, E, and G). Therefore, mutations of L26 would
probably destabilize the entire protein. We attempted to minimize
any possible disruption to the secondary and tertiary structure of
Figure 1. The NMR structure of Vpr shows solvent exposed
hydrophobic residues along helices 1 and 3. (A) A wire and box
diagram of Vpr. The gray boxes represent the 3 helices of Vpr, and the
upper set of numbers denotes the boundaries of each helix. The lower
set of numbers identifies exposed hydrophobic residues along helix 1
and helix 3. (B) A tube diagram of the side view of the nuclear magnetic
resonance (NMR) structure of HIV-1 Vpr (PDB: 1M8L) indicating
hydrophobic amino acids exposed on the apparently solvent exposed
surfaces of helix 1 (red) and helix 3 (blue). (C) A space filling diagram of
the side view of HIV-1 Vpr using a hydrophobicity color scheme. The
exposed hydrophobic residues along helices 1 and 3 are colored as in
(B). Positively charged or polar amino acids with high hydrophilicity are
colored light blue. Purple residues are negatively charged with high
hydrophilicity. Polar amino acids with low to neutral hydrophobicity are
gray, and highly hydrophobic, nonpolar residues are brown. The a-
carbon peptide chain is black as in (B). (D) C-terminal end view of HIV-1
Vpr helical core indicating the hydrophobic patches colored as in (B). (E)
A space filling end view as in (D) colored as in (C). (F) Top view of HIV-1
Vpr helical core indicating the hydrophobic patches colored as in (B).
(G) Top view of HIV-1 Vpr using a space filling diagram colored as in (C).
doi:10.1371/journal.pone.0024924.g001
Figure 2. Hydrophobic residues on Vpr helix-1 are important
for incorporation into virions. (A) 293T cells were co-transfected
with pcDNA3-hVpr plasmids expressing WT or mutant Vpr (or the
empty vector control), pLVSV-G, and pNL4-3e-n-GFP RTm, VprD22-86 to
produce virus for virion delivery of Vpr. At day 2 the virus stocks were
harvested and the 293T cells were lysed. Western blot indicates protein
levels for WT or mutant Vpr (bottom). A western blot for b-actin is used
as a loading control (top). (B) Lysates were prepared from the virus
stocks in (A). Viral lysates were analyzed for protein levels of WT or
mutant Vpr by western blotting as in (A) (bottom). The HIV-1 p24 capsid
(p24 CA) is shown as a protein loading control (top). (C) Densitometry
of all bands in (B) was performed. The intensity of the Vpr protein band
was normalized to p24 CA and plotted as % Vpr incorporation relative
to WT Vpr for each mutant. The data are shown as the mean 6 the
standard deviation of three independent experiments.
doi:10.1371/journal.pone.0024924.g002
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groups.
In the previous analysis, some of the Vpr helix-3 mutants could
not be expressed [18]. Therefore, we first tested the expression of
the helix-1 mutants by western blot analysis as previously
described [41]. All Vpr mutants expressed at similar levels as
WT Vpr in HEK293T cells (Figure 2A). Since helix-1 of Vpr is
responsible for the incorporation into budding virions by binding
to the p6 region of Gag [30,31,32,45], we also studied the helix-1
mutants for Vpr incorporation by producing non-replicative virus
using a reverse transcriptase mutant and Vpr deficient strain of
HIV-1 (NL4-3e-n-GFPRT
m, VprD22-86) and trans-complementing
Vpr with separate expression plasmids as previously described
[18,41]. Although expression was comparable in the 293T
producer cells, WT and mutant Vpr were differentially packaged
into virions (Figure 2B–C). We calculated the percent of Vpr that
is incorporated into the virions (relative to WT Vpr) by comparing
the relative intensities (by densitometry analysis of the western
blots) of the Vpr protein bands to the p24 capsid structural protein.
All of the Vpr helix-1 mutants were packaged into virions at
approximately 40–80% of the level of WT, except for L22E, which
was only ,20% compared to WT (Figure 2C).
We first characterized the cell cycle arrest activity of the helix-1
mutants by using virion delivery of Vpr (Vprv) as previously
described [18,41]. We titrated the amount of WT Vprv to provide
matched control levels of Vpr for the mutants. All of the mutants
Figure 3. Hydrophobic residues on Vpr helix-1 are important for virion-delivered Vpr cell cycle arrest. WT or mutant Vpr proteins
(denoted by the single letter amino acid changes) were delivered (Vprv) into Jurkat cells. Virions containing WT Vpr were titrated (md, medium) so
that a matched Vpr protein control could be compared to the mutants. (A) Western blot of the Jurkat cells for WT and mutant virion-delivered Vpr
(bottom). b-actin is shown as a protein loading control (top). (B) Histograms of cell cycle analysis at 41 hr post-infection show DNA content of PI-
stained cells by flow cytometry. All samples represent 10,000 cellular events. G1 and G2/M populations were modeled using the Watson Pragmatic
cell cycle model, and the G2,M/G1 ratio in each infection is shown. The data are representative of three experiments.
doi:10.1371/journal.pone.0024924.g003
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dose of WT Vprv (G2,M/G1=4.6) by western blot analysis
(Figure 3A). Interestingly, mutation of W18 to any of the substitute
residues (A, S, or E) greatly reduced the Vpr-induced G2/M arrest
(Figure 3B). Glutamic acid had the greatest effect (G2,M/
G1=1.4), as predicted, since the negatively charged glutamic
acid should disrupt the chemical nature of the hydrophobic patch
to the greatest degree. W18 may assist the binding to a partner
protein through stacking interactions of the aromatic ring
structure, which could explain why all mutations of this residue
had a pronounced effect. The alanine substitution of L22 had no
effect on Vprv cell cycle arrest. However, the L22S (G2,M/
G1=3.2) and the L22E (G2,M/G1=1.7) mutations reduced the
G2/M arrest (Figure 3A).
Transient transfection can also be used to evaluate Vpr-induced
cell cycle arrest [18,41]. Equivalent expression of the mutants was
confirmed by western blot analysis, and all of the mutants were
expressed at a similar level as the WT sample relative to the
loading control (Figure 4A). The same cell cycle trend was found
with transfection as with virion delivery. All substitutions for W18
reduced cell cycle arrest. Whereas the L22A mutation had
minimal effect, mutations to S and E both showed less
accumulation of cells in G2/M than WT (Figure 4B). These
results indicate that the exposed hydrophobic patch on Vpr helix-1
Figure 4. Exposed hydrophobic residues on Vpr helix-1 are important for transfected Vpr G2/M arrest. Jurkat cells were co-transfected
with pcDNA3-hVpr plasmids expressing WT or mutant Vpr (or the empty vector control) and pEGFP-N1 as a transfection marker at a ratio of 5:1. (A)
Western blot of the Jurkat cells for WT or mutant Vpr (bottom). A western blot of b-actin was used as a protein loading control (top). (B) Histograms
of cell cycle analysis at 61 hr post-transfection show DNA content of GFP+, PI-stained cells by flow cytometry. All samples represent 10,000 cellular
events. G1 and G2/M populations were modeled using the Watson Pragmatic cell cycle model, and the G2,M/G1 ratio in each transfection is shown.
The data are representative of three experiments.
doi:10.1371/journal.pone.0024924.g004
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delivered Vprv system.
The previous study on the helix-3 hydrophobic patch (I63, I67,
and I74) found a correlation between cell cycle arrest and
cytopathicity for the mutants using virion delivered Vprv [18]. We
examined the helix-1 mutants for a similar correlation. WT and
mutant Vpr was delivered into Jurkat cells, and the cell cycle
profile and viability of these cells were assessed over time as
previously described (Figure 5) [18]. Similar to the previous report,
we found that wild type Vprv reduced the cell viability to
approximately 65% over the course of infection (Figure 5B). G2/
M arrest correlated with the toxicity of the helix-1 mutants during
virion delivery (Figure 5C). The L22A mutant, which has
comparable cell cycle arrest function as WT, also showed similar
cell death activity (Figure 5). The other mutants exhibited reduced
cytopathicity proportional to the reduction in cell cycle arrest. The
Figure 5. Vpr G2/M arrest correlates with cell death induced by virion delivery. (A) WT or mutant Vpr proteins (denoted by the single letter
amino acid changes) were delivered (Vprv) into Jurkat cells, and separately Jurkat cells were co-transfected with pcDNA3-hVpr plasmids expressing
WT or mutant Vpr (or the empty vector control) and pEGFP-N1 as a transfection marker at a ratio of 5:1. Infected and transfected cells were analyzed
for DNA content of the PI-stained cells by flow cytometry. G1 and G2/M populations were modeled using the Watson Pragmatic cell cycle model, and
the G2,M/G1 ratios were plotted on the x-axis. (B) The viability of the Vprv-treated cells was monitored over time by flow cytometry (detection of
PI-negative, forward-scatter high events), and the percentage of viable cells is plotted over time. These data are representative of three experiments.
(C) The G2,M/G1 ratios and viability of Vprv-treated cells at 165 hour post-infection from three independent experiments were plotted.
Each measurement is color-coded as in (B). Spearman’s rank test was used to determine the correlation.
doi:10.1371/journal.pone.0024924.g005
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in toxicity, corresponding with the most attenuation of G2/M
arrest (Figure 5). Although cell cycle arrest correlated with cell
death among the Vpr mutants, some discrepancies still existed. For
example, Vpr L22S caused more arrest than both W18A and
W18S (Figure 5A); yet L22S caused less death than W18A/S
(Figure 5B). These results suggest that the exposed hydrophobic
residues along Vpr helix-1 are important for cytopathicity, and
that G2/M arrest frequently correlates with cell death, similar to
the results with the helix-3 mutants [18].
Discussion
Vpr likely functions by binding with partner proteins [1,2,28],
and our lab has previously shown a role for the exposed
hydrophobic patch along Vpr helix-3, an expected protein-protein
interaction site, in the G2/M cell cycle arrest and cell death
functions [18]. Here, we present an analysis of another expected
protein binding domain, the hydrophobic patch of Vpr helix-1, for
Vpr-induced G2/M arrest and cytopathicity, as well as virion
incorporation. Although, the expected defect in virion incorpora-
tion was observed with the mutations we created, this is the first
examination specifically of the hydrophobic patch residues. The
L22E mutant was particularly impaired in virion incorporation,
suggesting that the introduction of a negative charge at this site
inhibits the binding of Vpr to the p6 region of the Gag
polyprotein. We found that the exposed hydrophobic amino acids
W18 and L22 are important for both G2/M arrest and
cytopathicity, and that these two properties of Vpr are correlated.
We found that specific mutants of W18 and L22 reduced cell
cycle arrest to varying degrees in both virion delivery of Vpr and
transient transfection. The differences between the mutations to A,
S, and E at each position were most apparent with Vprv due to the
higher degreeof cellcycle arrestcausedby this technique.However,
even though the differences were smaller using transfection, the
same trend was seen between the mutants (Figures 4 and 5A). The
correlation betweenG2/Marrestand Vpr-induced deathcausedby
Vprv is similar to our previous study of Vpr helix-3 [18]. However,
analysis of the helix-3 mutants in the context of HIV-1 infection did
not show reduced cytopathicity. This was due to a G1 arrest caused
by the mutant Vpr. Even though the infected cells exhibited a more
normal DNA content profile, the cells were still inhibited from
proliferating [18]. It would be interesting to test whether the helix-1
mutants relieve G2/M arrest but promote a G1 arrest during HIV-
1 infection, and thus still kill the infected cell.
Vpr is thought to mediate all of its known functions through the
binding of partner molecules [26,28]. We and others have shown
that Vpr binds to the 14-3-3 family of scaffold proteins [42,46].
This interaction induces a large molecular complex nucleated on
the 14-3-3 protein that consists of a number of cell cycle regulatory
proteins [42]. Recently, multiple groups have found that Vpr
binds to an E3 ubiquitin ligase comprised of DCAF1/VprBP,
DDB1, Cul4, and Roc1 [16,47,48,49,50,51,52]. Vpr is proposed
to recruit an unknown but critical cell cycle component into the E3
ligase complex and induce the abnormal degradation of that
unknown cell cycle protein. This mechanism has already been
shown to occur for the UNG2 protein [15,16,17]. Perhaps the
hydrophobic patch of Vpr helix-1 and/or helix-3 participates in
the interaction between Vpr and any of these partner proteins.
Thus, it would be interesting to examine the role of exposed
hydrophobic residues along these a-helices (W18, L22, I63, L67,
and I74) in Vpr-dependent molecular complexes.
A close examination of our data and the results of the helix-3 study
reveals that none of the mutants completely abrogated G2/M arrest
[18]. However, all of these mutants only substitute a single residue. It
is possible that a single change in either of the hydrophobic patches is
not enough of a disruption of the chemical nature of the putative
protein interaction site. Therefore, testing combinations of mutants,
suchasW18Aand L22A,mayfurtherreducecellcyclearrestandcell
death cause by Vpr. Another possibility is that the exposed
hydrophobic amino acids along both Vpr helices could actually
comprise one protein interaction site. The hydrophobic side groups
do orient to the same outward ‘‘half’’ of the core of Vpr (Figure 1).
However,the‘‘ridge’’ofargininesalonghelix-3(Figure1C,E,andG)
would likely disrupt the continuity of a single large hydrophobic
patch. Perhaps mutations in both patches are necessary to completely
inhibit the G2/M arrest function.
We have previously shown that HIV-1 causes a necrotic death
of the host CD4
+ T cells and T cell lines [53,54]. The accessory
proteins Vpr and Vif are independently able to cause this
cytotoxicity [19]. Interestingly, both Vpr and Vif are able to
induce a G2/M cell cycle arrest, suggesting that cell cycle arrest
may be the cause of HIV-induced necrosis [19,42]. In fact,
mutants of the exposed hydrophobic residues of Vpr helix-3 cause
a G1 cell cycle arrest in the context of HIV-1 infection. This G1
arrest still leads to the death of the host cell, indicating that any
inhibition of proliferation of HIV-1 infected cells will cause the
death of the cell [18]. It would be interesting to test whether the
helix-1 mutants also induced a G1 arrest in the context HIV-1
infection leading to cell death. Further investigation into the exact
mechanism linking cell cycle arrest to cytopathicity could provide
possible targets for therapies that would reduce the depletion of
CD4
+ T cells during HIV-1 infection.
We found that the exposed hydrophobic amino acids W18 and
L22 are important for both G2/M arrest and cytopathicity, and
that these two properties of Vpr are correlated. Although this is
not the first study to implicate the amino-terminal region of Vpr in
cell cycle arrest, there are unresolved questions in the previous
mutagenesis findings. Mutations of hydrophobic core residues,
such as A30L [29] and H33R [40], would likely cause misfolding
of the protein around the core [27]. Introduction of proline
residues into the first a-helix, such as the E21,24P mutation [30],
would destroy the helical structure of that region, and probably
alter the entire global structure of Vpr [26]. We cannot be certain
that the W18 and L22 mutations that we introduced did not
significantly alter Vpr structure without further structural
examination. However, these residues do not interact with the
hydrophobic core of the protein, and disruption of the local
secondary structure by the substitute residues is unlikely.
Therefore, this is the first study showing a role for the helix-1
hydrophobic patch in Vpr-induced G2/M arrest and cytotoxicity.
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